Spectral Medical (STU:SD4) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:SD4 Spectral Medical Inc STU:SD4
14 GF Score
Price €0.83
GF Value €0.56
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Spectral Medical Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:SD4
14GF Score
Spectral Medical Inc STU:SD4
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Spectral Medical (STU:SD4) Overvalued in 2026?

Based on GuruFocus' analysis, Spectral Medical stock appears to be overvalued. The current stock price of €0.83 is trading 47.3% above its estimated GF Value™ of €0.56. GuruFocus considers Spectral Medical to be Significantly Overvalued.

Key valuation signals for STU:SD4:

  • Dividends Received:
  • GF Value™: €0.56 vs. price of €0.83 (47.3% above fair value)
  • GF Score™: 14/100 with 9 warning signs

No single metric tells the full story. See the STU:SD4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Spectral Medical Business Description

Other Exchanges EDTXF:USAEDT:Canada
Address 135 The West Mall, Unit 2, Finance, Toronto, ON, CAN, M9C 1C2
Spectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the Toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. Its products include an endotoxin activity assay, a rapid in-vitro diagnostic test used to measure endotoxin levels in blood, and a polymyxin B hemoperfusion device designed to remove endotoxin from the bloodstream. The company's proprietary reagents include recombinant proteins, antibodies, and calibrators used in research and diagnostic applications.
14GF Score

Get the complete analysis for STU:SD4

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.83
Price
€0.56
GF Value